Our data reveal that specific deletion of Vegfr2 on myeloid cells led to reduced response to VEGF blockade in a syngeneic breast cancer model, highlighting the importance of VEGFR2+ myeloid cells for the efficacy of anti-VEGF therapy. Here, VEGFA is linked to breast cancer.